Gökhan S. Hotamisligil

Science

Low-impact change.

Impact 39.3 · Hidden · Confidence 75

• Adds a 2025 strategic alliance (Enlila) linking Hotamisligil's lab to Harvard's tech transfer office and İş Private Equity, with translational aims for obesity, cardiovascular and aging-related diseases.

Add: In 2025 the Hotamisligil laboratory signed into agreement a strategic alliance with Harvard's Office of Technology Development and İş Private Equity to form Enlila a biotech venture whose aim is to translate the groundbreaking research from the Hotamişlıgil Laboratory into therapeutics for obesity cardiovascular and age related diseases.

Read the article on Wikipedia. Text excerpts from Wikipedia are licensed under CC BY-SA 4.0.